The rise of the DOL doesn’t mean pharma should upend KOL approach.
By Read Roberts
With the rise of DOL influence, clients are asking whether their strategies
should focus specifically on DOLs in place of KOLs? We have found that both
groups are important. Although differences do exist between KOLs and DOLs, they
share commonalities. And reaching both may be easier than you think……
More in the complete article here on Pharm Exec.com,
Published on March 10, 2023, Pharmaceutical Executive, March 2023, Volume 43, Issue 2
